$280 Wednesday, November 9, 2005 Poster Abstracts

Methods: The safety of GaI-ER and GaI-IR (titrated by 8-mg increments over 4-week intervals to 16 or 24 mg/d) was assessed in a 6-month, randomized, double-blind, placebo-controlled trial in 965 patients with mild to moderate Alzheimer's disease. Results: Nausea and vomiting were reported by 16.9% and 6.6% of patients administered GaI-ER (n - 319) and 13.8% and 8.6% administered GaI-IR (n -- 326), respectively. Nausea was reported on 3.17,'8 GaI-ER and 5.2% GaI-IR treatment days (P -- 0.14) and vomiting on 0.6% GaI-ER and 1.67,'8 GaI-IR treatment days (P - 0.20). In subjects reporting nausea, duration (measured as percent nausea days) was significantly shorter in the Gal-ER versus GaI-IR group (18.4% versus 38.0%; P - 0.014). Corresponding values for vomiting were 8.5?,'8 versus 19.1%, P -- 0.35. During the 12-week titration phase, lower rates of nausea or vomiting occurred in the Gal- ER (maximum, 6.6%; week 10) versus the GaI-IR group (maxinmm, 8.1%; week 9). Onset of nausea was strongly correlated with dose increase in the Gal-ER group (P < 0.01) and during titration, nausea rates were lower in the GaI-ER group compared to the GaI-IR group. Few subjects discontinued treatment due to nausea (137,'8, Gal- ER; 2?,'8, GaI-IR), even though more were titrated to the higher dose of GAL-ER. Conclusions: Among subjects with nausea, the duration of nausea was significantly shorter with the once-daily GaI-ER fommlation than with Gal-IR.

0707 Primary Progressive Aphasia. Language Improvement After Therapy with Do nepezfl

Bua, G 1, Rotondo, A 2, Salvo, R 2, Nieddu, A 2. ZNeurology Service and Alzheimer's Unit, Polidinieo Sassarese S.p.A., Sassari, Italy.." 2Geriatry Unit and Alzheimer's Unit, Polielinieo Sassarese S.p.A., Sassari, Italy

Background: Primary progressive aphasia (PPA) is clinically defined as a progressive language deficit that remains relatively isolated from other cognitive or behavioural defcits for at least 2 years. At the moment there is no a formal therapy for this deficit and language rehabilitation does not show a significative improvement. We describe a single case study where a patient has a significative improvement in language production after adininistation of donepezil and language rehabilitation. Method: A language assessment was administered with global neuro- psychological evaluation, neuroimaging study and clinical evaluation over a 4-year follow-up. After an episode of agitation and global worsening of cognitive functions we administered donepezil 5 mg/die and the patient showed a marked improvement in language production and global functions compared with the previous 4 years. Results: After one, four and six months follow-up the patient shows a significative improvement of language compared with the previous period. Conclusions: We think that donepezil improved language functions enhacing hemispherics neural activity, presumably facilitating brain plasticity through long-term potentiation. In our case this activity could be potentiated by a concomitant language rehabilitation.

Our results are lirnitated and we think that a randomized, double- blind, controlled study is needed to demonstrate the potential benefit of donepezil in patient with APP.

0708 Cognitive Impairment hi tile Metabolic Syndrome: a case-coulrol study in the Spanish population

Cacho, J, Gamazo, S, Sevillano, D, Chong, Y, Rodriguez-Perez, R, Fernandez-Cairo, B. Universitary Hospital of Salamanca

Background: Vascular risk factors (Hypertension, Diabetes Mellitus and Hyperlipidenffa) have been involved in the appearance of cognitive impairment. The Metabolic Syndrome (MS), diagnosed of agreement

with the criteria of the National Cholesterol Educational Program (NCEP), has been described recently as a new entity responsible of cognitive impairment. Objective: The aim of tiffs study is to compare the performance of a group of patients with Metabolic Syndrome (MS), diagnosing according NCEP criteria, against a control group of healthy control (HC) subjects in a general cognitive battery (Dementia Rating Scale - DRS-2-). Patients and Methods: The authors have studied 78 subjects, 30 patients with MS (38, 46%), with a mean age of 73, 83 and no clinical dementia; and 48 subjects (61,54%) HC, with a mean age of 70,57. Results: Patients in the MS group obtained significantly lower scores on the DRS-2 that the HC group. The Risk Ratio (RR) is 2, 15 (CI: 1, 27-3, 66). Conclusions: In our study, the MS patients show a cognitive impairment (evaluated with DRS-2) against subjects with HC.

0709 Treahnent of Multi - Infarct Dementia

Omndra, B ~. 1Airlangga University, Indonesia

Multi infarct dementia (MID) is not a rare disease, but until now there is no standard therapy. The diagnosis of MID is based on the Mini Mental State Examination (MMSE) and the Ischemic Scale of Hachinski. Computed tomography was performed in all patients and magnetic resonance imaging in some. All patients who fulfilled these criteria were requested to participate.

Informed consent was obtained from the family. The project began January 1, 1984 and ended January 1, 2005. Six patients refused to participate. The remaining 438 patients were allocated randomly into two groups, one receiving 250 mg citicholine four times a day and the other receiving isotonic saline four times a day, for two months.

The doctor, nurse and patients did not know which ampules contained citicholine and which contained isotonic saline because both were identical. The patients were followed for 10 months. The group treated with citicholine showed a marked improvement on the MMSE compared with the placebo group (p < 0.01). To prevent a recurrence both groups received aspirin 100 mg/day. Citicholine is probably working as a neuro protective agent.

0710 The alteration of serum interleukin-10 and soluble interleuldn-6 receptor levels in patients with Alzhehner's disease

Chen, S 1, Gan, J 1, Tang, H 1, Wang, y1. ZDepartment of Neurology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China

Objective: To investigate the level of interleukin- 10 (IL- 10) and soluble interleukin-6 receptor (sIL-6R) in serum of patients with Alzheimer's disease (AD) and its correlation with severity of AD. Methods: The concentrations of serum IL-10 and sIL-6R were measured by means of an enzyme-linked immunosorbent assay in 46 AD patients, 40 cerebral infarction patients and 33 healthy control subjects. Results: The level of IL- 10 was significantly decreased in AD patients, compared with both cerebral infarction (CD patients and healthy control subjects, but did not differ between CI patients and healthy control subjects. SIL-6R content was significantly increased in AD patients, especially in the severe AD patients, No statistical difference in the concentration of SIL-6R was noted between AD patients and CI patients. Conclusions: Alteration of serum IL-10 and sIL-6R levels is found in AD patients, demonstrating that inflanunation is involved in the pathological process of AD.